New Missouri Rural Health Program Directs Resources to Rural Communities to Improve Social Care Outcomes
The Missouri HealthNet Division introduces a new care model that utilizes the Unite Us Payments solution to create sustainability for...
Year: 2024
Scryb Announces Development of New Enterprise AI Venture
Toronto, Ontario--(Newsfile Corp. - February 14, 2024) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") is pleased...
Unveiling Fortifeye Rejuvenate Collagen
A Groundbreaking Formula for Health and VitalityOCALA, FL / ACCESSWIRE / February 14, 2024 / Fortifeye Vitamins, a leading provider...
Unveiling Fortifeye Rejuvenate Collagen
A Groundbreaking Formula for Health and VitalityOCALA, FL / ACCESSWIRE / February 14, 2024 / Fortifeye Vitamins, a leading provider...
Skinvisible Announces Significant Progress in Licensee’s Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising...
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by...
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data...
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and...
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in FullSOLANA BEACH, Calif., Feb. 14, 2024...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel...
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose...
Microbix Reports Record Results for Q1 Fiscal 2024
Record Revenues of $8.4 million and Record Net Income of $2.5 millionMISSISSAUGA, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Microbix...
Shineco Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
BEIJING, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced...
Healthcare Triangle Unveils New SaaS Solutions to Drive Digital Transformation and AI Integration in Healthcare
Company positioned at forefront of $208 billion global AI in healthcare market by 2030 PLEASANTON, Calif., Feb. 14, 2024 (GLOBE...
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical...